TAZICEF
Approved
Approval ID
40d48c5d-650e-461b-a67b-7e65772d1b92
Product Type
HUMAN PRESCRIPTION DRUG LABEL
Effective Date
Mar 10, 2023
Manufacturers
FDA
Hospira, Inc.
DUNS: 141588017
Products 2
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
CEFTAZIDIME
PRODUCT DETAILS
NDC Product Code0409-5082
Application NumberANDA062662
Marketing CategoryC73584
Route of AdministrationINTRAMUSCULAR, INTRAVENOUS
Effective DateMarch 10, 2023
Generic NameCEFTAZIDIME
INGREDIENTS (2)
CEFTAZIDIMEActive
Quantity: 1 g in 1 1
Code: 9M416Z9QNR
Classification: ACTIM
SODIUM CARBONATEInactive
Quantity: 118 mg in 1 1
Code: 45P3261C7T
Classification: IACT
CEFTAZIDIME
PRODUCT DETAILS
NDC Product Code0409-5084
Application NumberANDA062662
Marketing CategoryC73584
Route of AdministrationINTRAVENOUS
Effective DateMarch 10, 2023
Generic NameCEFTAZIDIME
INGREDIENTS (2)
CEFTAZIDIMEActive
Quantity: 2 g in 1 1
Code: 9M416Z9QNR
Classification: ACTIM
SODIUM CARBONATEInactive
Quantity: 236 mg in 1 1
Code: 45P3261C7T
Classification: IACT